Get the Stockscreener App
2.67
16.04%
-0.51
Context Therapeutics Inc stock is traded at $2.67, with a volume of 1.72M.
It is down -16.04% in the last 24 hours and up +9.88% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$3.18
Open:
$3.22
24h Volume:
1.72M
Relative Volume:
1.11
Market Cap:
$245.32M
Revenue:
-
Net Income/Loss:
$-36.12M
P/E Ratio:
-6.9459
EPS:
-0.3844
Net Cash Flow:
$-28.42M
1W Performance:
-8.56%
1M Performance:
+9.88%
6M Performance:
+195.65%
1Y Performance:
+208.67%
1-Day Range:
$2.5801
$3.33
1-Week Range:
$2.5801
$3.33
52-Week Range:
$0.49
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.67 | 292.18M | 0 | -36.12M | -28.42M | -0.3844 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
Context updates corporate presentation, flags interim CTIM-76/CT-95/CT-202 milestones; cash runway into mid-2027 - TradingView
Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway - Stock Titan
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) EstimateContext Therapeutics (NASDAQ:CNTX) - Benzinga
With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan
CNTX: Net loss rose to $36.1M in 2025; $66M cash funds operations into mid-2027, more capital needed - TradingView
Context Therapeutics (NASDAQ: CNTX) advances three T cell engager programs - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Surprises Report: How does Bausch Health Companies Inc perform in inflationary periods2026 Key Lessons & Daily Stock Momentum Reports - baoquankhu1.vn
Context Therapeutics to Present Poster at AACR Annual Meeting - National Today
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Loss Report: Is Context Therapeutics Inc stock risky to hold now2026 Dividend Review & Expert Curated Trade Ideas - baoquankhu1.vn
HR Positive/ HER2 Negative Breast Cancer Clinical Trial - openPR.com
HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
CNTX PE Ratio & Valuation, Is CNTX Overvalued - Intellectia AI
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - MarketBeat
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Context Therapeutics Inc. Files 8-K and Certificate of Correction to Amended and Restated Certificate of Incorporation (March 11, 2026) - Minichart
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - TipRanks
Board terms change at Context Therapeutics (NASDAQ: CNTX) after court ruling - Stock Titan
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Quarterly Earnings: How does Context Therapeutics Inc compare to its peersWeekly Profit Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Context Therapeutics (CNTX) to Release Earnings on Thursday - MarketBeat
Movement Recap: Can Context Therapeutics Inc stock double in the next yearPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market Expected - openPR.com
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Context Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch - Meyka
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference - MarketBeat
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy - Cantech Letter
CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):